Serum Adropin as an Indicator of Endothelial Dysfunction and Disease Severity in Obstructive Sleep Apnea in Obese Patients

1\. Objectives (Aim): To evaluate the role of serum adropin as a potential biomarker of endothelial dysfunction in OSA 1. Compare serum adropin levels between Obese patients with and without OSA. 2. Correlate serum adropin with OSA severity indices including the Apnea-Hypopnea Index (AHI) and Oxygen Desaturation Index (ODI) and cardiovascular complications. 3. Assess the relationship between serum adropin and endothelial dysfunction markers (endothelin-1). 4. Evaluate adropin's predictive ability for endothelial impairment among OSA patients.

Inclusion Criteria: * 1- Adults aged 20-75 years. 2-obese Patients diagnosed with obstructive sleep apnea (OSA) confirmed by polysomnography. 3- Patients willing to provide written informed consent. 4- Patients not currently on medications affecting endothelial function (e.g., statins, ACE inhibitors) or able to temporarily withhold under medical supervision. 5- Ability to comply with study procedures and follow-up Exclusion Criteria: * 1-Pregnant females 2-Thyroid disorders 3-Autoimmune diseases 4-chronic liver disease 5-chronic kidney disease 6-drugs as statin,glucocorticoids and antidepressant